The Filing Desk

Mereo BioPharma Group vs Scienture

Mereo BioPharma Group MREO · Scienture SCNX · Pharmaceuticals

Mereo BioPharma Group reported revenue of $0 million in fiscal 2025, 1.2 times Scienture's $0 million in fiscal 2025. Mereo BioPharma Group had an operating margin of -8021.4%, against -9867.9% at Scienture.

Side by side

Mereo BioPharma GroupScienture
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$0M$0M
Revenue growth—215.9%
Revenue growth a year, last 5 years—−52.8%
Gross margin—76.8%
Operating margin−8,021.4%−9,867.9%
Net margin−8,375.6%−9,618.0%
Free cash flow−$31M—
Free cash flow margin−6,198.2%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count7.8%320.1%
Last close$0.28$2.44
P/E at the last close——
Insider trades, last 12 months——
Piotroski F-score4 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Mereo BioPharma GroupScienture
Operating margin
Percent of revenue
Mereo BioPharma GroupScienture
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Mereo BioPharma GroupScienture

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Mereo BioPharma Group and Scienture pages.